Publications by authors named "E B Dennehy"
Recent advances in development of amyloid-targeting therapies support the potential to slow the rate of progression of Alzheimer's disease. We conducted a narrative review of published evidence identified through a targeted search of the MEDLINE and EMBASE databases (2020-2023), recent presentations at disease-specific conferences, and data updates from cohort studies in Alzheimer's disease to describe the trajectory of the progression of Alzheimer's disease. Our findings enable the interpretation of clinical trial results and the value associated with slowing disease progression across outcomes of relevance to patients, care partners, clinicians, researchers and policymakers.
View Article and Find Full Text PDFArticle Synopsis
- The Integrated Alzheimer's Disease Rating Scale (iADRS) is a comprehensive tool used to measure the severity of Alzheimer's disease by integrating cognitive and functional abilities into a single score, allowing for better interpretation of clinical findings from studies like TRAILBLAZER-ALZ.
- Recent findings from the TRAILBLAZER-ALZ study showed that the Alzheimer's treatment donanemab effectively slowed disease progression by 32% over 18 months, making the iADRS a vital measure in evaluating the impact of disease-modifying therapies (DMTs).
- Overall, the iADRS is a reliable assessment method in clinical trials for early symptomatic Alzheimer's patients, as it can accurately reflect clinical changes and treatment effects.
Objective: The robust enrollment in SPARTAN and SAMURAI provided the opportunity to present post-hoc descriptive details on migraine disease characteristics and treatment outcomes after treatment with lasmiditan, a selective serotonin (5-HT) receptor agonist, in racial and ethnic subgroups.
Methods: Descriptive data from racial (White [W]( = 3471) and Black or African American [AA]( = 792)) and ethnic (Hispanic or Latinx [HL]( = 775) and Non-Hispanic or Latinx [Non-HL]( = 3637)) populations are presented on pooled data from two double-blind, placebo-controlled, randomized Phase 3 studies (SAMURAI [NCT02439320] and SPARTAN [NCT2605174]). Patients were treated with lasmiditan (50 (SPARTAN only), 100, or 200 mg) or placebo for a single migraine attack of moderate-to-severe intensity.
Objective: To evaluate the efficacy of lasmiditan (LTN) in treating migraine attacks of mild vs. moderate or severe pain intensity.
Methods: Pooled data from two single-attack, placebo-controlled studies (SAMURAI [NCT02439320] and SPARTAN [NCT02605174]), and a prospective, randomized, open-label study (GLADIATOR [NCT02565186]) were assessed.
Introduction: Lasmiditan is a selective serotonin (5-HT1F) receptor agonist approved in the US for the acute treatment ofmigraine in adults. This phase I, open-label, two-cohort study assessed the pharmacokinetics (PK), safety, and tolerability of lasmiditan in patients with migraine aged 6 to < 18 years.
Methods: Cohort 1 (15 to ≤ 40 kg) and Cohort 2 (> 40 to ≤ 55 kg) received single oral doses of lasmiditan (100 mg and 200 mg, respectively).